Therapeutic flag Cosmetic cross-reference

Nitrous Oxide

CAS 10024-97-2

Nitrous Oxide (CAS 10024-97-2) is a Phase 3 pharmaceutical compound with 0 bioactivity targets and 191 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral / FAERS
Adverse signals
191
SOURCE IUPHAR / PharmGKB
PubMed IDs
2
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Nitrous Oxide
CAS Number
10024-97-2
UNII
K50XQU1029
InChIKey
GQPLMRYTRLFLPF-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1234579
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural producttherapeutic flag
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL1234579 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 2023 / FAERS disproportionality 65 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Anaesthetic complication neurological 115 766.567 10002105
Subacute combined cord degeneration 64 466.555 10042272
Choroidal infarction 41 308.537 10057403
Hyperthermia malignant 40 185.438 10020844
Cardiac arrest 86 125.583 10007515
Myelopathy 32 123.626 10028570
Vitamin B12 deficiency 34 116.286 10047609
Bradycardia 72 108.038 10006093
Anaesthetic complication 24 99.011 10060938
Drug interaction 107 92.539 10013710
Laryngospasm 23 84.976 10023891
Leukoencephalopathy 23 70.513 10024382
Apnoea 25 66.696 10002974
Epilepsy with myoclonic-atonic seizures 10 64.506 10081179
Neuromuscular block prolonged 13 59.907 10029314
Procedural vomiting 13 59.379 10066963
Bladder agenesis 10 59.092 10056655
Congenital ectopic bladder 9 59.022 10010453
Delayed recovery from anaesthesia 14 58.857 10012206
Procedural nausea 13 58.675 10066962
Lipodystrophy acquired 17 56.984 10049287
Cloacal exstrophy 10 56.697 10067424
Gastrointestinal disorder congenital 9 53.298 10061973
Tethered cord syndrome 10 52.934 10066334
Vitamin B12 decreased 16 52.724 10047608
Meconium stain 10 52.21 10057028
Genitalia external ambiguous 10 50.781 10018183
Drug use disorder 18 49.877 10079381
Caudal regression syndrome 9 47.846 10059387
Drug abuse 47 47.829 10013654
Gastrointestinal malformation 9 47.629 10061596
Change in seizure presentation 10 47.547 10075606
Congenital genital malformation 9 47.459 10062333
Umbilical cord abnormality 10 45.378 10048596
Pulmonary oedema 36 44.257 10037423
Neuromuscular blockade 9 43.086 10029315
Anal atresia 10 43.061 10002120
Ventricular tachycardia 26 42.498 10047302
Disinhibition 13 41.841 10013142
Fatigue 4 41.665 10016256
Meningomyelocele 10 40.56 10027287
Respiratory depression 22 40.423 10038678
Air embolism 8 38.624 10001526
Substance dependence 8 37.497 10076595
Exomphalos 9 37.317 10015677
Brain oedema 20 37.311 10048962
Diarrhoea 3 37.31 10012735
Blood homocysteine increased 8 37.043 10049733
Hypoxia 34 36.812 10021143
Neural tube defect 8 36.388 10052046

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE PharmGKB drug-gene phenotypes 4 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

MTHFR (PA245) rs1801131
Genotype GG is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype TT.
Evidence: -; PMID 18580170
MTHFR (PA245) rs1801133
Genotype AA is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype GG.
Evidence: -; PMID 18580170
MTHFR rs1801133
-
Evidence: 3; PMID 1
MTHFR rs1801131
-
Evidence: 3; PMID 1
SOURCE RxNorm drug names 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
NITROUS OXIDE 7486 SU MTHSPL
Nitrous Oxide 7486 SU MTHSPL
nitrous oxide 7486 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Nitrous Oxide used for in pharmaceutical contexts?

Nitrous Oxide (CAS 10024-97-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Nitrous Oxide?

Nitrous Oxide has 191 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Anaesthetic complication neurological, Subacute combined cord degeneration, Choroidal infarction, Hyperthermia malignant, Cardiac arrest. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Nitrous Oxide also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for NITROUS OXIDE with EU status "permitted".

What clinical phase is Nitrous Oxide in?

Nitrous Oxide is rendered with ChEMBL max phase 3.